ライフサイエンスコーパス: cobimetinib

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 inhibitor vemurafenib and the MEK inhibitor cobimetinib.

2 the concomitant addition of a MEK inhibitor, cobimetinib.

3 t combined vemurafenib with a MEK inhibitor, cobimetinib.

4 fenib 960 mg twice a day in combination with cobimetinib 60 mg 21/7.

5 hedule of vemurafenib 960 mg twice a day and cobimetinib 60 mg 28/0 had dose-limiting toxic effects-o

6 hedule of vemurafenib 960 mg twice a day and cobimetinib 60 mg once a day 21/7 had a grade 3 prolonga

7 20 mg or 960 mg twice a day continuously and cobimetinib 60 mg, 80 mg, or 100 mg once a day for eithe

8 ng an interactive response system to receive cobimetinib (60 mg once daily for 21 days followed by a

9 en dosing regimens combining vemurafenib and cobimetinib: 66 had recently progressed on vemurafenib a

10 hedule of vemurafenib 960 mg twice a day and cobimetinib 80 mg once a day 14/14 had grade 3 fatigue f

11 n this genotype with GDC-0973 (also known as cobimetinib), a MEK inhibitor currently in phase III cli

12 hibitor of the PI3K/mTOR pathway, along with cobimetinib, a MEK/ERK pathway inhibitor.

13 on in most patients: 109 (93%) of 117 in the cobimetinib and vemurafenib group and 133 (94%) of 142 i

14 of 259 patients have died: 117 (47%) in the cobimetinib and vemurafenib group and 142 (58%) in the v

15 events occurred in 92 patients (37%) in the cobimetinib and vemurafenib group and 69 patients (28%)

16 ing at a higher frequency in patients in the cobimetinib and vemurafenib group compared with the vemu

17 utamyl transferase increase (36 [15%] in the cobimetinib and vemurafenib group vs 25 [10%] in the pla

18 ommon serious adverse events reported in the cobimetinib and vemurafenib group.

19 22.3 months (95% CI 20.3-not estimable) for cobimetinib and vemurafenib versus 17.4 months (95% CI 1

20 rvival was 12.3 months (95% CI 9.5-13.4) for cobimetinib and vemurafenib versus 7.2 months (5.6-7.5)

21 The safety profile for cobimetinib and vemurafenib was tolerable and manageable

22 iving different MEK inhibitors (selumetinib, cobimetinib, and trametinib) developed an eruption, all

23 positive melanoma to receive vemurafenib and cobimetinib (combination group) or vemurafenib and place

24 These data confirm the clinical benefit of cobimetinib combined with vemurafenib and support the us

25 pictilisib (GDC-0941) and the MEK inhibitor cobimetinib (GDC-0973) suppresses cell proliferation and

26 ion with vemurafenib and MEK inhibition with cobimetinib in patients with advanced BRAF-mutated melan

27 s were enrolled and randomly assigned to the cobimetinib plus vemurafenib group (n=247) or placebo pl

28 The addition of cobimetinib to vemurafenib was associated with a signifi

29 Vemurafenib and cobimetinib was associated with a nonsignificantly highe

30 The combination of vemurafenib and cobimetinib was safe and tolerable when administered at

31 All patients treated with vemurafenib and cobimetinib were included in safety and efficacy analyse

32 The combination of cobimetinib with vemurafenib improves progression-free s

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。